Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05MPS
|
|||
| Former ID |
DNC014566
|
|||
| Drug Name |
MYOSEVERIN
|
|||
| Synonyms |
myoseverin; 267402-71-1; 9-Isopropyl-N2,N6-bis-(4-methoxybenzyl)-9H-purine-2,6-diamine; 9-Isopropyl-N2,N6-bis(4-methoxybenzyl)-9H-purine-2,6-diamine; AC1L1HSM; AC1Q4VJQ; 9-Isopropyl-2,6-bis(4-methoxybenzylamino)purine; CHEMBL141689; SCHEMBL13325947; CTK8E8888; MolPort-003-958-703; HMS2043N15; KS-000012SJ; ZINC2583630; n,n'-bis(4-methoxybenzyl)-9-(propan-2-yl)-9h-purine-2,6-diamine; HSCI1_000041; IN1218; AKOS027326433; TRA0035814; SMP2_000092; NCGC00165829-01; ACM267402711; RT-013973; M2373; J-016534
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C24H28N6O2
|
|||
| Canonical SMILES |
CC(C)N1C=NC2=C(N=C(N=C21)NCC3=CC=C(C=C3)OC)NCC4=CC=C(C=C4)OC
|
|||
| InChI |
1S/C24H28N6O2/c1-16(2)30-15-27-21-22(25-13-17-5-9-19(31-3)10-6-17)28-24(29-23(21)30)26-14-18-7-11-20(32-4)12-8-18/h5-12,15-16H,13-14H2,1-4H3,(H2,25,26,28,29)
|
|||
| InChIKey |
IDCOTQWQVPRTNK-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tubulin (TUB) | Target Info | Inhibitor | [1] |
| Tubulin beta (TUBB) | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Phagosome | |||
| Gap junction | ||||
| Pathogenic Escherichia coli infection | ||||
| NetPath Pathway | FSH Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| EGFR1 Signaling Pathway | ||||
| Panther Pathway | Cytoskeletal regulation by Rho GTPase | |||
| Huntington disease | ||||
| Reactome | Regulation of PLK1 Activity at G2/M Transition | |||
| Loss of Nlp from mitotic centrosomes | ||||
| Recruitment of mitotic centrosome proteins and complexes | ||||
| Loss of proteins required for interphase microtubule organization?from the centrosome | ||||
| Anchoring of the basal body to the plasma membrane | ||||
| WikiPathways | Parkin-Ubiquitin Proteasomal System pathway | |||
| Pathogenic Escherichia coli infection | ||||
| Mitotic G2-G2/M phases | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Synthesis and biological evaluation of myoseverin derivatives: microtubule assembly inhibitors. J Med Chem. 2001 Dec 20;44(26):4497-500. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.